ABSTRACT
This paper addresses the subject of how PBMs structure prior approval, prescribing restrictions, and appeal procedures for off-la- bel indications, expensive therapies, or fast-track drugs. I will begin by describing ValueRx's experience in managing high-cost drug therapy cases. My comments focus on procedural issues and include a review of a case study that I hope will serve as an example of how the program works.
